Cryptococcosis is a global invasive mycosis that is associated with high morbidity and mortality. Patients with HIV infection are at a significantly increased risk of developing this fungal disease. With its profound propensity to locate within the central nervous system (CNS), *Cryptococcus spp.* frequently causes fungal meningitis. In fact, this encapsulated yeast remains the most common cause of meningitis in HIV-infected individuals living in sub-Saharan Africa. It is estimated that in 2014 there were over 220,000 new cases of cryptococcal meningitis globally resulting in more than 180,000 deaths and is responsible for 15% of all AIDS-related deaths. Although the annual rate of cryptococcal disease has decreased after the widespread use of highly active anti-retroviral therapy (HAART) in developed countries, the prevalence of cryptococcal infection remains at a high level in low and middle-income countries despite the availability of HAART ([@B75]). The one-year mortality after cryptococcal meningitis ranges from 10-30% in North America to up to 50-100% in low-income countries ([@B60], [@B79], [@B78]).

Furthermore, non-HIV patient populations are also at risk of cryptococcal infection, notably transplant recipients and patients on immunosuppressive therapies. For example, approximately 2-3% of solid organ recipients have been found to develop cryptococcal infection with most patients presenting with disseminated infection ([@B34], [@B42], [@B48], [@B55]). With over 33,000 solid organ transplants performed in the United States alone in 2016, the number of cryptococcal infection cases remains unacceptably high ([@B24]). With our increasing use of immune-modulators from corticosteroids, biological modifiers (i.e. anti-TNF and anti-CD54) to new anti-cancer agents such as ibrutinib ([@B45]), we can expect the number of patients with cryptococcosis to remain concerning ([@B20]).

Antifungal drug therapy remains the mainstay of treatment of these cryptococcal infections. This review aims at highlighting the drugs and strategies utilized for the management of this life- threatening infection, as well as the new developments in treatment.

*Therapeutic principles for cryptococcal meningitis* - Before examining the details of our arsenal, several therapeutic principles for management of cryptococcal meningitis should be listed: (1) early diagnosis is helpful to a successful outcome of treatment with a lower burden of yeasts and less destruction from a persistent, dysregulated immune system; (2) identification of new, old, and changing risk factors is necessary to properly utilize our outstanding biomarkers for disease; (3) a fungicidal anticryptococcal regimen that rapidly clears viable yeasts from the subarachnoid space is optimal management; (4) major complications of cryptococcal meningitis should be carefully identified and managed. These include (a) increased intracranial pressure and (b) development of the immune reconstitution inflammatory syndrome (IRIS); (5) further understanding of *in vitro* anticryptococcal yeast susceptibility testing for resistance (there are no validated drug break points) and strain evaluation genetically for identification of possible "bad actor" strains will be helpful. This area requires further research to become more clinically relevant and precise; (6) we must control the concomitant underlying diseases at all costs and this will likely demand attention to the "Goldilocks's Paradigm of Immunology, not too much and not too little but must get it just right"; (7) our goal is to reduce mortality but it must also be accompanied by a reduction in morbidity, which is less chronicled in present reviews.

*Amphotericin B & flucytosine (5-FC)* - The polyene, amphotericin B, has been the mainstay of treatment of cryptococcal meningitis in HIV-infected individuals and transplant recipients as well as non-HIV and non-transplant patients for several decades. Using a polyene-based regimen has been associated with significant reduction of the yeast burden within the CNS and is correlated with improved survival ([@B71]. Furthermore, the combination of amphotericin B with 5-FC has been shown to be the most fungicidal regimen at present in the clinics and is associated with improved survival among those with cryptococcal meningitis compared to amphotericin B treatment alone ([@B35], de [@B15], [@B9], [@B18], [@B14], [@B71]. Recently, a large randomized study (ACTA) with over 700 patients confirmed the superiority of this combination ([@B28]. In medically-developed countries, using the combination of amphotericin B and 5-FC for induction of HIV-infected patients with cryptococcal meningitis in a three-part strategy of induction-consolidation-maintenance is recommended at a dose of amphotericin B deoxycholate of 0.7-1 mg/kg/day intravenously with 5-FC 100 mg/kg/day orally for at least two weeks ([@B56]. Studies that have assessed the use of the higher dose of amphotericin B (1 mg/kg/day vs. 0.7 mg/kg/day) with 5-FC found that despite the improved fungicidal activity, the number of serious adverse events related to higher doses increased ([@B7].

Substituting lipid formulations of amphotericin B for amphotericin B deoxycholate is favored in most patients in medically developed countries and particularly in transplant recipients who are at significantly higher risk of nephrotoxicity due to their potential concomitant use of other nephrotoxic drugs such as calcineurin inhibitors ([@B11], [@B68], [@B37], [@B3], [@B70], [@B22]). Liposomal amphotericin B or amphotericin B lipid complex are recommended at a dose of 3-4 mg/kg/day or 5 mg/kg/day, respectively ([@B56]). Extending the induction period depends on the prognosis and response of the individual at the time. In general, there is a switch toward primary use of lipid products of amphotericin B in resource-available health care systems and shorter course amphotericin B therapy (one week) in resource-limited healthcare systems for the induction period.

*Azoles: fluconazole* - Fluconazole is used in the three-part strategy of induction-consolidation-maintenance in combination with amphotericin B as a substitute for 5-FC in the induction phase when 5-FC is not available as well as alone in the consolidation and maintenance phases for cryptococcal meningitis ([@B56]). Fluconazole has a fungistatic effect on cryptococcal meningitis and so the burden of yeast must be low or dose of fluconazole must be very high for it to have a significant therapeutic impact in the CNS ([@B41], [@B64], [@B1], [@B77], [@B49]). For this reason, reduction of fungal burden with amphotericin B in combination with fluconazole is necessary for successful outcome in resource-limited settings ([@B65], [@B23], [@B44], [@B62], [@B6]). Although amphotericin B and fluconazole in combination are not as potent as amphotericin B plus 5-FC, it clearly can effectively be used in induction therapy at higher doses of fluconazole of ≥ 800 mg/day ([@B55]). The use of high dose fluconazole as monotherapy for induction therapy is still associated with significantly higher mortality than combination therapy and needs further investigation to implement successful monotherapy regimens in resource-limited settings ([@B51], [@B19]). However, the use of fluconazole with 5-FC in combination as an all oral regimen continues to be studied and most recent data suggest that it is not significantly inferior to the amphotericin B- containing regimens ([@B28]).

Following induction therapy, relatively high doses of fluconazole are used in the consolidation phase for a recommended period of eight weeks and this has been shown to be superior to other azoles such as itraconazole ([@B56], [@B5]).

The last phase of the three-part strategy, suppression or maintenance, is also continued with fluconazole if the patient is stable after consolidation. The use of a suppression strategy has been validated by several studies, due to the high relapse rate of cryptococcal meningitis prior to HAART (15%) ([@B57]). Fluconazole was shown to be superior to itraconazole and even weekly amphotericin B for suppression ([@B57]). Suppression with fluconazole is generally continued for at least one year in HIV patients and for 6-12 months in non-HIV patients ([@B56]). In HIV patients, after successful introduction of HAART, discontinuing suppressive therapy with ﬂuconazole is recommended when CD4 ≥ 100 cell/µL and an undetectable HIV RNA level is sustained for ≥ 3 months ([@B56]).

For other cryptococcal infections, such as pulmonary cryptococcosis, fluconazole monotherapy is recommended as treatment for mild to moderate disease ([@B56]).

*Itraconazole, voriconazole and posaconazole* - The extended-spectrum azoles have a limited experience in treatment of cryptococcosis. Itraconazole has successfully treated cryptococcal meningitis but its poor absorption and limited CNS penetration makes it unreliable ([@B10], de [@B15], [@B59]. Voriconazole, which does penetrate into the CNS well, has had some success in primary treatment, particularly in normal hosts ([@B80]. Posaconazole has excellent activity against *Cryptococcus spp.* but has limited CNS penetration. The largest series of cryptococcal meningitis treatment with posaconazole had 14/29 (48%) success ([@B59].

*Isavuconazole* - The VITAL study was an open label phase III trial to assess the use of oral and intravenous isavuconazole for primary or salvage therapy of *Cryptococcus spp.* and dimorphic mycoses infections. Of the nine patients with cryptococcal infections receiving isavuconazole, 67% had either success, partial success or stable disease with an all-cause mortality of 11%. Furthermore, preliminary data suggests that isavuconazole has adequate CNS penetration and might likely have a role in treating cryptococcal meningitis and CNS infections, but further studies are necessary. Adverse events occurred at around 37% with this azole but were more favorable than amphotericin B and none of the patients discontinued therapy due to adverse events ([@B76]).

*HAART* - HAART during management of cryptococcal meningitis is a double-edged sword. On the one hand, it could improve the immune response to the infection but on the other, it might contribute to IRIS as well as possess drug interactions and toxicity to curtail the management plan. Deciding when to initiate HAART is critical. Delaying HAART for five weeks after diagnosis and initiation of antifungal therapy improved survival compared to only one-two weeks ([@B82]) and clearly, early use of HAART in first two weeks of cryptococcal meningitis treatment increased deaths ([@B8]). Current recommendations suggest delaying HAART for two-10 weeks after initiation of antifungal therapy ([@B56]). Furthermore, in resource-limited countries with difficulty implementing wide spread HAART for HIV patients, initiating HAART within four-five weeks might be required to adequately control the severe underlying disease.

*Combination screening & pre-emptive therapy* - Cryptococcal antigen (CrAg) can be detected in serum more than three weeks prior to onset of symptoms of cryptococcal meningitis. Global cryptococcal antigenemia in 2014 was estimated at 6% of HIV-infected patients with CD4 counts less than 100 cells/µL, translating to approximately 280,000 individuals ([@B60]. Asymptomatic cryptococcal antigenemia is well known to occur in patients with HIV infection ([@B40]. Furthermore, HIV-infected patients with low CD4 counts who have a positive CrAg have significantly higher mortality ([@B17], [@B50], [@B74], [@B39], [@B47]. As a result, the World Health Organization (WHO) recommended that HIV patients with CD4 ≤ 100 cells/µL should be tested for cryptococcal antigenemia ([@B43]. If tested positive, asymptomatic patients would be given oral fluconazole for pre-emptive antifungal therapy unless titer was high (≥ 1:160) in which case CSF should be examined for presence of meningitis ([@B38], [@B43]. This strategy was shown to not only decrease cryptococcal disease and improve survival, but has proven cost-effective in resource-limited countries with high incidences of disease ([@B46], [@B29], [@B43]. The development of cheaper lateral flow assays can be utilized with an accuracy of nearly 100% to diagnose cryptococcal disease and even suggest prognosis, with each 2-fold increase in titers associated with higher mortality at two and 10 weeks ([@B27]. Therefore, in resource-limited areas with high antiretroviral drug resistance and significant prevalence of cryptococcal disease, a CrAg screening and preemptive therapy strategy should be considered ([@B73].

*Immunotherapy* - Despite the abundance of in-vitro and in-vivo studies demonstrating the significant contribution of immune modulation to the course of cryptococcal infections, there is a lack of sufficient clinical data to make strong recommendations for the use of immunotherapy in treating these infections ([@B2]). In murine models of cryptococcal infections, administering IL-12 and IL-18 have been shown to significantly reduce the fungal cell burden in many organs and enhance elimination of *Cryptococcus spp..* These murine models have also shown an increase in IFN-γ after administering IL-12 or IL-18, with anti IFN-γ antibodies eliminating the protective effect of the interleukins ([@B33], [@B31]). Direct administration of IFN-γ prolonged survival in murine models of cryptococcosis ([@B32]). Administration of TNF-α in-vitro increased the anticryptococcal activity of macrophages and combining TNF-α with granulocyte-macrophage colony stimulating factor enhanced phagocytosis by murine macrophages ([@B12], [@B30]. Murine models using TNF-α related antibodies decreased fungal cell burden, mediated by an increase in IFN-γ ([@B81]. A study of 62 HIV patients receiving antifungal therapy for cryptococcal meningitis showed that survivors compared to non-survivors had higher CSF concentrations of IFN-γ, TNF-α, IL-6 and 8 ([@B69]. Furthermore, some non-HIV, non-transplant and supposedly immunocompetent patients with cryptococcal disease have been shown to possess autoantibodies to GM-CSF ([@B66].

With this very supportive background for immunotherapy, several human studies have been performed. First a phase II trial evaluating the use of adjuvant recombinant IFN (rIFN)-γlb in HIV patients with cryptococcal meningitis showed accelerated clearance of CSF cultures but results did not achieve statistical significance ([@B54]). Second, another recombinant interferon-gamma study showed a positive effect on the reduction of yeasts in the CSF without adverse effects ([@B26]). Despite these two positive studies for adjunct recombinant gamma interferon current guidelines have a low level recommendation for the addition of rIFN-γ to the antifungal regimen of patients with persistent cryptococcal infection ([@B56]). This hesitancy to elevate immunomodulation therapy as first line therapy in the induction regimen may be due to concerns about monitoring for appearance of IRIS in CNS infections and the general lack of robust clinical trials.

Other immunotherapeutic options being studied involve the use of monoclonal antibodies targeting virulence factors of *Cryptococcus spp.* such as capsule, as well as radiolabelled monoclonal antibodies to deliver radiation to cryptococcal cells and induce an apoptosis-like cell death ([@B36], [@B2]).

*Adjuvant steroid use* - Given that adjuvant steroid use in patients with other types of meningitis like tuberculosis and some types of bacterial meningitis has been shown to reduce morbidity and mortality, a large clinical trial was performed to evaluate the combination of dexamethasone with amphotericin B and fluconazole antifungal therapy. The trial was stopped early due to the increased mortality at 10 weeks and six months as well as more adverse events in the group receiving dexamethasone compared to placebo. The adverse events included progression of infections, nephrotoxicity and cardiac toxicity. Furthermore, the addition of corticosteroids reduced the fungicidal activity of the drugs ([@B4]). However, it is important to note that this study evaluated the routine administration of dexamethasone at the beginning of therapy and not its use in management of IRIS. There have been some expert opinions on the use of steroids to curb intrathecal inflammation after achieving microbiological control ([@B53]). A study involving patients with cryptococcal spinal arachnoiditis showed that excessive inflammation prolonged symptoms that later improved with administration of corticosteroids ([@B52]). Therefore, despite the disadvantages of routine use of dexamethasone in treatment of cryptococcal meningitis, it is important to recognize that steroid therapy may be life-saving during IRIS. A taper of corticosteroids can be considered over two-six weeks, based mainly on expert opinions.

*Lumbar puncture (LP)* - Studies have shown that raised intracranial pressure (ICP) in cryptococcal meningitis is associated with increased mortality ([@B21]). The withdrawal of CSF appears to be effective in reducing intracranial pressure caused by an outflow obstruction of the arachnoid villi by clumping yeasts ([@B16]). A lumbar puncture to control ICP and symptoms has been recommended and a study evaluating the impact of therapeutic LPs on survival showed a 69% relative improvement associated with therapeutic LPs irrespective of initial ICP, suggesting that any patient with cryptococcal meningitis may benefit ([@B56], [@B63]). Hence, utilizing therapeutic LPs in the management of cryptococcal meningitis must be considered at times but its precise use and frequency are not yet defined.

*New strategies: advancing cryptococcal meningitis treatment for Africa (ACTA)* - ACTA is a phase III trial aimed at finding more feasibly implemented regimens for resource-limited healthcare systems and to determine if 5-FC or fluconazole is better adjuvant treatment. Three treatment strategies were compared: (1) an all oral strategy, of high-dose fluconazole and 5-FC for two weeks; (2) amphotericin B plus either high-dose oral fluconazole/5-FC for one week only; (3) amphotericin B plus high dose fluconazole / 5-FC for two weeks (control). An early presentation from the trial revealed that the short course arms of amphotericin B and the all-oral fluconazole/5-FC were non-inferior to the control group. Furthermore, using 5-FC as adjuvant therapy with amphotericin B led to lower mortality compared with fluconazole. The one-week amphotericin B plus 5-FC arm had the lowest mortality among the treatment arms ([@B28]).

*AmBisome plus high dose fluconazole for treatment of HIV-associated cryptococcal meningitis (AMBITION-cm)* - AMBITION-cm is a phase II randomized, controlled, non-inferiority trial that has recently shed some light on the use of a few large doses of liposomal amphotericin B with high dose fluconazole for the treatment of cryptococcal meningitis in HIV patients. The short-course high-dose polyene arms received one, two or three doses of liposomal amphotericin B while being given a high-dose fluconazole backbone regimen. Data has shown the rate of clearance of CSF cultures in all the short-course, high-dose arms to be non-inferior to the standard two-week course of daily polyene, with none of the participants necessitating any treatment interruptions. The single dose (10 mg/kg/day) liposomal amphotericin B regimen is being taken to a phase III trial ([@B25]). These new strategies have the potential to reduce cost and toxicity.

*Pipeline drugs* - APX001 is a first-in-class antifungal compound inhibiting fungal protein Gwt1 with no cross-reaction with the human protein. It has recently been shown that combining APX001 with fluconazole will reduce the fungal burden in mice with cryptococcal meningitis significantly compared to either agent alone. It also has the added advantage of oral bioavailability and even more potent anticryptococcal compounds in this class have been discovered ([@B67]). AR-12, a celecoxib derivative, repurposed for antifungal therapy, inhibits fungal acetyl-CoA synthase I and down regulates host chaperone proteins that reduce host immune response. It has shown antifungal activity against *Cryptococcus spp.* as well as candida and moulds ([@B58]). T-2307, an allylamine that inhibits fungal mitochondrial membrane potential has been shown to have extremely potent antifungal activity *in vitro* and against cryptococcosis in animal models. The azoles have further evolved and with new technology to reduce CYP450 interactions, several compounds, VT1129 and VT1598, have shown outstanding fungicidal activity in murine models of cryptococcosis ([@B58]).

In the area of repurposing available drugs, both sertraline and tamoxifen have the potential to be used in combination with existing antifungal drugs for treatment of cryptococcal meningitis and cryptococcosis. In fact, sertraline has been successfully used in a pilot study and a more definitive trial is heading toward completion ([@B61]). The calcineurin pathway has also been shown to be an important factor in cryptococcal virulence and utilizing calcineurin inhibitors such as tacrolimus / cyclosporine in combination with antifungal drugs could have potential in the future. However, it is likely that it will be necessary to discover congeners of these landmark drugs that possess more potent antifungal activity but also reduced immunosuppressive activities ([@B58]).

*Neurapheresis* - Neurapheresis is a new, potential technology for managing cryptococcal meningitis that is currently in development. Cryptococcal meningitis causes an increase in CSF pressure by mechanical occlusion of the arachnoid villi and thus rapid killing and removing yeasts from the subarachnoid space may change our management of cryptococcal meningitis. Utilizing the size of the encapsulated yeast, neurapheresis involves mechanically filtering the CSF from the subarachnoid space (SAS) using a membrane with pores ≤ 5 μm in diameter to trap the fungus. A peristaltic pump circulates the CSF of rabbits with cryptococcal meningitis through this filter and reintroduces it back into the SAS. After six hours of cycling through the filter, the fungal colony forming units in the CSF were reduced by up to 99%. Further studies may aim at combining neurapheresis with direct antifungal drug delivery such as amphotericin B intrathecally to create high efficacy regimens along with systemic antifungal agents ([@B13]).

*In conclusion* - Mortality and morbidity still remain high for cryptococcal meningitis despite several strategies for management. Infections in the CNS can be unforgiving and therefore, all tools available must be utilized. Complications such as increased intracranial pressure and IRIS must be recognized and treated despite unclear guidelines. Early diagnosis, expert care ([@B72]) and rapidly fungicidal regimens will allow more optimal management. However, clearly, the discovery of more potent and less toxic antifungal agents will be helpful to reduce the negative impact of this CNS fungal infection. We are poised today to make an improvement in our antifungal arsenal tomorrow.
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